Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Shanghai Benemae Pharmaceutical Corporation manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These cases are distributed among 5 distinct examiners across 3 distinct art units. BUTTICE, AUDREY L is the busiest examiner, though she only handles 1 pending office action. The high number of examiners relative to the number of art units suggests a broad engagement with different personnel at the patent office.
This distribution indicates that the company is navigating multiple parallel paths within its chosen technology sector. With 5 distinct examiners involved, the portfolio is less susceptible to the specific biases of a single individual. However, the concentration within 3 distinct art units suggests that while the examiners vary, the technical focus remains relatively consistent. Practitioners should coordinate strategies across these different examiners to ensure consistent claim construction and avoid conflicting arguments during the prosecution of these 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
| HELLMAN, KRISTINA M | 1 | 65.3% | +55.3% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324935 | NOVEL ANTI-LAG3 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME | BUTTICE, AUDREY L | 71d overdue |
| 17813285 | DOSING REGIMEN OF GLP-1 | HELLMAN, KRISTINA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15045068 | STABLE AQUEOUS PARENTERAL PHARMACEUTICAL COMPOSITIONS OF INSULINOTROPIC PEPTIDES | KOMATSU, LI N | 86d overdue |
| 17015500 | GLP-1 COMPOSITION FOR TREATING OBESITY AND WEIGHT MANAGEMENT | SABILA, MERCY HELLEN | 73d overdue |
| 18324935 | NOVEL ANTI-LAG3 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME | BUTTICE, AUDREY L | 71d overdue |
| 17813284 | COMBINATIONAL THERAPY COMPRISING GLP-1 AND/OR GLP-1 ANALOGS, AND INSULIN AND/OR INSULIN ANALOGS | BEANE, RANDALL L | — |
| 17813285 | DOSING REGIMEN OF GLP-1 | HELLMAN, KRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1654 | 3 |
| 1647 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324935 | NOVEL ANTI-LAG3 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME | BUTTICE, AUDREY L | 1647 | §101§102§103§112 | Final Rejection | 71d overdue | Pending | May 26, 2023 |
| 17813284 | COMBINATIONAL THERAPY COMPRISING GLP-1 AND/OR GLP-1 ANALOGS, AND INSULIN AND/OR INSULIN ANALOGS | BEANE, RANDALL L | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Jul 18, 2022 |
| 17813285 | DOSING REGIMEN OF GLP-1 | HELLMAN, KRISTINA M | 1654 | §102§112 | Non-Final OA | — | Pending | Jul 18, 2022 |
| 17015500 | GLP-1 COMPOSITION FOR TREATING OBESITY AND WEIGHT MANAGEMENT | SABILA, MERCY HELLEN | 1654 | §103DP | Non-Final OA | 73d overdue | Pending | Sep 09, 2020 |
| 15045068 | STABLE AQUEOUS PARENTERAL PHARMACEUTICAL COMPOSITIONS OF INSULINOTROPIC PEPTIDES | KOMATSU, LI N | 1658 | §103 | Final Rejection | 86d overdue | Pending | Feb 16, 2016 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial